Catalent Acquires UK Biologics Facility
CDMO will invest up to $160 million toward manufacturing of therapies and vaccines, including mRNA
Catalent, a contract development and manufacturing organization (CDMO), has purchased a biologics development and manufacturing facility that is currently under construction near Oxford, UK, from Vaccine Manufacturing and Innovation Centre UK Limited.
The CDMO plans to financially commit up to $160 million in order to complete the building of the facility and equip it with state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, featuring mRNA, proteins, and other advanced modalities. It is anticipated that the new facility will employ more than 400 people and support public and private organizations looking to develop and manufacture biotherapeutics.
“… Our priority is to complete construction as soon as possible to be able to commence customer programs in 2022,” says Mike Riley, president of Catalent Biotherapeutics. “We will then integrate its capabilities within our existing network of biologics facilities across Europe to offer a flexible range of manufacturing, technology, and development solutions for the pipeline of thousands of development programs currently underway.”
